Galapagos aquires Sareum's drug discovery assets
This article was originally published in Scrip
Executive Summary
Galapagos, the Belgian drug discovery company, is to acquire the structure-based drug discovery assets of UK-based Sareum for €695,000. Galapagos will acquire all of Sareum's ongoing structure-based drug discovery services contracts, a set of protein target structures called the Crystal Bank, a fragment screening library and equipment needed to perform structure-based drug discovery. Sareum's structure-based platform uses X-ray crystallography to discover chemical fragments for recombination, which the company says has accelerated drug discovery in many of its programmes. Galapagos said the assets would strengthen the position of its service division BioFocus DPI and that the acquisition would contribute slightly to the subsidiary's revenue target for this year. The Belgian company has reiterated its full year revenue guidance of €75-80 million. BioFocus DPI will also acquire five of Sareum's employees to operate the platform. Sareum began considering the sale of all or part of its business in May after it began a review of its operations amid difficult trading (ScripOnline, May 7th, 2008).
You may also be interested in...
Myotec and Hybrid merge to form PsiOxus
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
Trophos's MitoCare programme receives €6 million EU funding
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Novartis and Alcon reach compromise to settle merger saga
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.